New Insights and Clinical Implications for the Treatment of ALK+ NSCLC

Sunday, September 23, 2018
9:45 AM – 11:15 AM
Room 105, North Building,
Metro Toronto Convention Centre (MTCC)
Toronto, Canada

Breakfast to be provided

This program was approved by the IASLC 19th World Conference on Lung Cancer Program Committee as an independent activity held in conjunction with the IASLC 19th World Conference on Lung Cancer. This program is not sponsored or endorsed by IASLC.
New Insights and Clinical Implications for the Treatment of ALK+ NSCLC

FACULTY

Chair:
Natasha Leighl, MD, MMSc (Clin Epi), FRCPC, FASCO
Princess Margaret Cancer Centre
Toronto, Ontario, Canada

Robert C. Doebele, MD, PhD
University of Colorado Cancer Center
Colorado, USA

Karen Reckamp, MD
City of Hope Comprehensive Cancer Center
California, USA

Luis Paz-Ares, MD, PhD
Hospital Universitario Doce de Octubre
Madrid, Spain

AGENDA

9:45 AM - 9:52 AM Welcome and Introductions
7 min Natasha Leighl, MD, MMSc (Clin Epi), FRCPC, FASCO

9:52 AM - 10:14 AM Insights Into Mechanisms of Resistance and Characterizing Oncogenic Drivers in ALK+ NSCLC
22 min Robert C. Doebele, MD, PhD

10:14 AM - 10:36 AM Current Landscape of ALK Inhibitors and Key Data
22 min Karen Reckamp, MD

10:36 AM - 10:58 AM How to Integrate New Agents and Disease Monitoring Practices Into Optimal Patient Care
22 min Luis Paz-Ares, MD, PhD

10:58 AM - 11:13 AM Panel Discussion
15 min Faculty

11:13 AM - 11:15 AM Conclusion
2 min Natasha Leighl, MD, MMSc (Clin Epi), FRCPC, FASCO